Related Experiment Video
Updated: Jul 9, 2025

Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice
Published on: January 26, 2024
A novel holin from an Enterococcus faecalis phage and application in vitro and in vivo
Yingying Xiang1, Suping Wang2, Hao Huang1
1Department of Stomatology, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650031, China.
Abstract:
Enterococcus faecalis, a conditional pathogenic bacterium, is prevalent in the intestinal, oral, and reproductive tracts of humans and animals, causing a variety of infectious diseases. E. faecalis is the main species detected in secondary persistent infection from root canal therapy failure. Due to the abuse of antibacterial agents, E. faecalis has evolved its resistant ability. Therefore, it is difficult to treat clinical diseases infected by E. faecalis. Exploring new alternative drugs for treating E. faecalis infection is urgent. We cloned and expressed the gene of phage holin, purified the recombinant protein, and analyzed the antibacterial activity, lysis profile, and ability to remove bacterial biofilm. It showed that the crude enzyme of phage holin pEF191 exhibited superior bacterial inhibiting activity and a broader lysis host range compared to the parent phage PEf771. In addition, pEF191 demonstrated high efficacy in eliminating E. faecalis biofilm. The therapeutic results of the Sprague-Dawley (SD) rats model infected showed that pEf191 did not affect SD rats, indicating that pEF191 provided greater protection against E. faecalis infection in SD rats. Based on the 16 S rDNA data of SD rats intestinal microorganism population, holin pEF191 exhibited no impact on the diversity of intestinal microorganisms at the phylum and genus levels and improved the relative abundance of favorable bacteria. Thus, pEF191 may serve as a promising alternative to antibiotics in the management of E. faecalis infection.
Insights
Phage holin pEF191 shows strong antibacterial activity against Enterococcus faecalis, effectively removing biofilms and protecting rats without harming gut microbiota. This makes pEF191 a potential antibiotic alternative.
Area of Science:
- Microbiology
- Bacteriology
- Molecular Biology
Background:
- Enterococcus faecalis is a resilient pathogen causing persistent infections, particularly after root canal therapy.
- Antibiotic resistance in E. faecalis necessitates urgent exploration of novel therapeutic agents.
- Bacteriophage-derived proteins offer a promising avenue for combating resistant bacterial infections.
Purpose of the Study:
- To investigate the antibacterial potential of cloned phage holin pEF191 against Enterococcus faecalis.
- To evaluate the efficacy of pEF191 in eliminating E. faecalis biofilms and its therapeutic effects in a rat model.
- To assess the impact of pEF191 on the intestinal microbiota composition.
Main Methods:
- Cloning and expression of phage holin gene, purification of recombinant protein.
- Analysis of antibacterial activity, lysis profile, and biofilm removal capabilities of pEF191.
- In vivo therapeutic evaluation in Sprague-Dawley rats and 16S rDNA analysis of intestinal microbiota.
Main Results:
- Phage holin pEF191 demonstrated superior antibacterial and broader lysis host range compared to the parent phage.
- pEF191 effectively eliminated E. faecalis biofilms and showed significant therapeutic protection in infected rats.
- pEF191 did not negatively impact rat intestinal microbiota diversity and improved beneficial bacteria abundance.
Conclusions:
- Phage holin pEF191 exhibits potent antibacterial and anti-biofilm activity against Enterococcus faecalis.
- pEF191 is safe for in vivo use, showing no adverse effects on host animals or gut microbiota.
- Holin pEF191 represents a promising alternative to conventional antibiotics for managing E. faecalis infections.
More Related Videos
Related Concept Videos
Lysogenic Cycle of Bacteriophages
Lytic Cycle of Bacteriophages

